Clinical trials: Colorectal Cancer Metastatic to Liver
Colorectal Cancer, Liver Metastases
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
The primary aim of this study is to investigate whether the addition of the new anti-cancer drug bevacizumab (Avastin) to the combination of the chemotherapeutic agents capecitabine (Xeloda) and oxaliplatin (Eloxatin) reduces…
- Trial name
- NCT00394992
- Testing
- oxaliplatin+capecitabine, Oxaliplatin+capecitabine+bevacizumab
- Where
- Netherlands
- Volunteers
- 79 people
- Sponsor
- Dutch Colorectal Cancer Group
Colorectal Cancer, Metastatic Cancer
Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003753
- Testing
- dexamethasone, floxuridine, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases
This observational study will evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.
- Trial name
- PICASSO (NCT01343901)
- Testing
- Bevacizumab
- Where
- 126 sites in France
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Cancer of Colon, Cancer of Rectum
Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients Undergoing Cancer Surgery
To determine whether exercise and nutrition prehabilitation improves patient outcomes after cancer surgery
- Conditions
- Cancer of Colon, Cancer of Rectum, Liver Metastases
- Trial name
- SPECS (NCT04880772)
- Testing
- Prehabilitation
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- East Lancashire Hospitals NHS Trust
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
The Patients With CRLM Who Benefit More From Bevacizumab
Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive unresectable colorectal cancer liver metastases, providing a favorable approach…
- Trial name
- NCT06023173
- Testing
- Deep radiomics-based fusion model
- Where
- China
- Volunteers
- 307 people
- Sponsor
- Fudan University
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be…
- Conditions
- Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
- Trial name
- NCT03373188
- Testing
- Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Colorectal Cancer Stage III, Liver Metastasis Colon Cancer
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- NCT06111105
- Where
- 15 sites in Austria, Denmark and 3 more
- Volunteers
- 590 people
- Sponsor
- Claus Lindbjerg Andersen
HCC - Hepatocellular Carcinoma, Colorectal Cancer Metastatic
ctDNA Monitoring in Patients With HCC and mCRC
"Liquid biopsy" is a collective term that refers to the analysis of cancer-derived biomarkers isolated from the biological fluids of cancer patients.
- Trial name
- NCT07001085
- Testing
- Tumor Tissue Collection and NGS, Blood Collection for Plasma ctDNA, ctDNA Mutation Analysis via ddPCR
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Medical University of Warsaw
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Liver Metastasis
Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer
This is a prospective, multicenter, observational study designed to validate the predictive accuracy of a pre-developed multimodal deep learning model.
- Trial name
- NCT07392567
- Testing
- Multimodal Deep Learning Prediction Model
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tongji Hospital
Colorectal Cancer, Liver Metastases
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
General Objectives: To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in…
- Trial name
- NCT00153998
- Testing
- Cetuximab, Liver resection, Cetuximab and FOLFIRI
- Where
- 21 sites in Austria, Germany
- Volunteers
- 135 people
- Sponsor
- Technische Universität Dresden
Diseases of Liver, Colon Carcinoma
Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques
To compare 2 different image creation/processing techniques during a standard CT scan in order to "see" problems in the liver and learn which method provides better image quality.
- Conditions
- Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
- Trial name
- NCT03151564
- Testing
- Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR)
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
This is a first-in-human, Phase 1 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of exoASO-STAT6 (CDK-004) in patients with advanced Hepatocellular Carcinoma (HCC) and patients with liver…
- Conditions
- Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver, Colorectal Cancer Metastatic to Liver
- Trial name
- NCT05375604
- Testing
- CDK-004
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Codiak BioSciences
Colorectal Cancer
Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer
Colorectal cancer (CRC) is among the most common malignancies in China, and approximately half of all patients develop liver metastases.
- Trial name
- NCT07885384
- Testing
- Fruquintinib Combined With Capecitabine, Follow-up observation
- Volunteers
- 140 people
- Sponsor
- West China Hospital
Liver Metastases From Colorectal Cancer
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM).
- Trial name
- FOAM (NCT07109440)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Jules Bordet Institute
Unresectable Colorectal Liver Metastases
Isolated Liver Perfusion With Oxaliplatin
The primary goal of this research study is to determine a safe dose for the drug oxaliplatin when delivered by isolated hepatic perfusion.
- Trial name
- NCT01042691
- Testing
- Oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- David Bartlett
Colon Cancer, Pancreatic Cancer
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Background: Gastrointestinal tumors have a molecule called carbohydrate antigen 19-9 (CA19-9) in the tumors and blood. The agent MVT-5873 was designed to block this molecule.
- Conditions
- Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma
- Trial name
- NCT03801915
- Testing
- MVT-5873, pancreatectomy or hepatectomy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Liver Metastases From Colorectal Cancer (mCRC)
Radiomics of Colorectal Liver Metastases: Identification of New Prognostic Biomarkers.
Background: Liver metastases (CLM) affect about half of patients with colorectal cancer and dictate patients' prognosis. Prediction of prognosis is of paramount importance for patients allocation to the most adequate treatment…
- Trial name
- NCT06779734
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Istituto Clinico Humanitas
Colorectal Neoplasms, Liver Neoplasms
The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases
The aim of the study is to obtain information on FLT used in a PET-scan as a marker for the proliferation of colorectal liver metastases, so that the risk of recurrence can be identified in a noninvasive way, concerning patients…
- Trial name
- NCT00145665
- Testing
- FLT-PET scan
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Radboud University Medical Center